Vall d’Hebron is looking for volunteers to participate in the Phase IIb study of the HIPRA vaccine against COVID-19

Vall d’Hebron is looking for volunteers over the age of 18 who have received the Pfizer-BioNTech Comirnaty vaccine against COVID-19 at least 6 months ago.

05/11/2021

Vall d’Hebron is looking for volunteers over the age of 18 who have received the Pfizer-BioNTech Comirnaty vaccine against COVID-19 at least 6 months ago, to study a new vaccine under research that it is developing against COVID-19.

Volunteers will receive a booster dose of the new vaccine under investigation or a vaccine already on the market and will be monitored for up to a year to find out their safety and response (immunity).

The study has bee evaluated by the Ethics Committee of the Hospital Clínic de Barcelona and the Spanish Agency for Medicines and Health Products (AEMPS) with the participation of several Spanish hospitals.

Interested people can contact Vall d’Hebron via this form, via email at vacunacovid@vhebron.net or via phone at 692 08 37 39 or 93 489 42 37 (8AM-5PM).

Share it:

Notícies relacionades

Professionals

Subscribe to our newsletters and be a part of Campus Life

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.